Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2625

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2625
---
 may be impossible or
require substantial time and monetary expenditure. We cannot predict whether any such license or sublicense would be available at all
or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain
licenses or sublicenses from third parties to advance our research or allow commercialization of our product candidates. We may fail
to obtain any of these licenses or sublicenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable
to further develop and commercialize our product candidates, which could harm our business significantly.

Third
parties may assert that our employees, consultants or advisors have wrongfully used or disclosed confidential information or misappropriated
trade secrets.

As
is common in the biotechnology and biopharmaceutical industries, we collaborate with and/or employ and intend to collaborate with and/or
employ individuals who were previously affiliated with universities or other biotechnology or biopharmaceutical companies, including
those that operate in the same indications we do. Although no claims against us are currently pending, and although we try to ensure
that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual
property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary
to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings
relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management
personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have
a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our
operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources
to adequately conduct such litigation or proceedings. We may be unable to sustain the costs of such litigation or proceedings as a result
of our currently limited financial resources. Uncertainties resulting from the initiation and continuation of patent